EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Positron Emission Tomography/Computed Tomography (PET/CT) and Radioimmunotherapy of Head and Neck Cancer Patient Derived Xenografts in NRG Mice with Theranostic [64Cu]Cu-DOTA-Panitumumab F(ab′)2 and [177Lu]Lu-DOTA-Panitumumab F(ab′)2

Meysam Khosravifarsani, Conrad Chan iD, Anthony Ku, Noor Alsaden, Jalna Meens iD, Laurie Ailles iD, Scott Bratman iD, Raymond M Reilly iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.5c01009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Meysam Khosravifarsani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College St., Toronto, Ontario M5S 3M2, Canada. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Radioimmunotherapy, Head and Neck Neoplasms, Panitumumab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Institutes of Health Research, University of Toronto, Leslie Dan Faculty of Pharmacy, University of Toronto.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Head and neck squamous cell carcinoma (HNSCC) expresses epidermal growth factor receptors (EGFR) in 90% of cases. Here we studied PET/CT imaging of three clinically relevant HNSCC patient derived xenografts (PDX) with low (#61531), moderate (#73191) or high (#88955) EGFR expression in NRG mice using anti-EGFR [64Cu]Cu-DOTA-panitumumab F(ab′)2. We further assessed the effectiveness of β-particle-emitting [177Lu]Lu-DOTA-panitumumab F(ab′)2 for radioimmunotherapy (RIT) of these PDX. All PDX were visualized by PET/CT at 24 h postinjection (p.i.) of [64Cu]Cu-DOTA-panitumumab F(ab’)2. In addition, in mice with PDX #88955, an axillary lymph node metastasis was imaged by PET and lung metastases were imaged by SPECT/CT at 3 to 12 d p.i. of [177Lu]Lu-DOTA-panitumumab F(ab′)2. Tumor uptake of [64Cu]Cu-DOTA-panitumumab F(ab′)2 at 24 h p.i. was directly correlated with EGFR expression (6.7 ± 3.5%, 13.5 ± 2.5% and 16.7 ± 1.0% ID/g for PDX #61531, #73191 and #88955, respectively). Intravenous administration of 5.0 MBq (50 μg) of [177Lu]Lu-DOTA-panitumumab F(ab′)2 to healthy NRG mice caused no hematologic, liver or kidney toxicity or decrease in body weight. RIT with 4.0–5.0 MBq (50 μg) of [177Lu]Lu-DOTA-panitumumab F(ab′)2 decreased the tumor growth rate vs 0.9% NaCl by 2, 9 and 3.2-fold, respectively in mice with PDX #61531, #73191 and #88955 (P = 0.014, P < 0.001, P = 0.004). Treatment of mice with unlabeled DOTA-panitumumab F(ab′)2 did not decrease the tumor growth rate of PDX#61531 (P = 0.457) but modestly decreased the tumor growth rate of PDX #73191 by 1.3-fold (P = 0.024) and PDX #88955 by 1.4-fold (P = 0.027). RIT was EGFR-specific as irrelevant anti-HER2 [177Lu]Lu-DOTA-trastuzumab F(ab′)2 was not effective for treatment of PDX #73191 vs 0.9% NaCl (P = 0.282). RIT with [177Lu]Lu-DOTA-panitumumab F(ab′)2 was 3-fold more effective for treating moderately EGFR-expressing PDX #73191 than PDX #88955 with high EGFR expression. This may be explained by the human papilloma virus (HPV) positivity of PDX #73191 since HPV-positive HNSCC is more responsive to external radiation beam treatment. We conclude that [64Cu]Cu-DOTA-panitumumab F(ab′)2 and [177Lu]Lu-DOTA-panitumumab F(ab′)2 are a promising theranostic pair for PET/CT imaging and RIT of HNSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyRadioimmunotherapyHead and Neck NeoplasmsPanitumumabSquamous Cell Carcinoma of Head and NeckAnimalsMiceHumansLutetiumCopper RadioisotopesErbB ReceptorsRadioisotopesXenograft Model Antitumor AssaysFemaleRadiopharmaceuticalsCell Line, TumorTheranostic NanomedicineImmunoconjugates

Stichwörter der Autor:innen

PET/CTcopper-64head and neck cancerlutetium-177panitumumabpatient-derived xenografts (PDX)radioimmunotherapytheranostics

Substanzen

LutetiumCopper RadioisotopesErbB ReceptorsRadioisotopesPanitumumabLutetium-177Copper-64RadiopharmaceuticalsEGFR protein, humanImmunoconjugates

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College St., Toronto, Ontario M5S 3M2, Canada.
  • Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2M9, Canada.
  • Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 2C4, Canada.
  • Departments of Radiation Oncology, University of Toronto, Toronto, Ontario M5T 1P5, Canada.
  • Department of Medical Imaging, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
  • Joint Department of Medical Imaging, University Health Network, Toronto, Ontario M5G 2C1, Canada.

ORCID-Profile: Conrad Chan, Jalna Meens, Laurie Ailles, Scott Bratman, Raymond M Reilly

Förderung

  • Canadian Institutes of Health Research
  • University of Toronto
  • Leslie Dan Faculty of Pharmacy, University of Toronto
  • New Frontiers in Research Fund Transformation (NFRF-T) Rare Isotopes to Transform Cancer Therapy program
  • Ontario Institute for Cancer Research

Zitieren

APA

Khosravifarsani, M., Chan, C., Ku, A., Alsaden, N., Meens, J., Ailles, L., Bratman, S., & Reilly, R. M. (2025). Positron Emission Tomography/Computed Tomography (PET/CT) and Radioimmunotherapy of Head and Neck Cancer Patient Derived Xenografts in NRG Mice with Theranostic [64Cu]Cu-DOTA-Panitumumab F(ab′)2 and [177Lu]Lu-DOTA-Panitumumab F(ab′)2. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01009

Vancouver

Khosravifarsani M, Chan C, Ku A, Alsaden N, Meens J, Ailles L, et al. Positron Emission Tomography/Computed Tomography (PET/CT) and Radioimmunotherapy of Head and Neck Cancer Patient Derived Xenografts in NRG Mice with Theranostic [64Cu]Cu-DOTA-Panitumumab F(ab′)2 and [177Lu]Lu-DOTA-Panitumumab F(ab′)2. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c01009

BibTeX
@article{Khosravifarsani2025,
  author = {Khosravifarsani, Meysam and Chan, Conrad and Ku, Anthony and Alsaden, Noor and Meens, Jalna and Ailles, Laurie and Bratman, Scott and Reilly, Raymond M},
  title = {Positron Emission Tomography/Computed Tomography (PET/CT) and Radioimmunotherapy of Head and Neck Cancer Patient Derived Xenografts in NRG Mice with Theranostic [64Cu]Cu-DOTA-Panitumumab F(ab′)2 and [177Lu]Lu-DOTA-Panitumumab F(ab′)2},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.5c01009}
}
Kostenlos starten →